KYMR - Kymera Therapeutics, Inc.
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR N
NEW YORK, May 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday that benefited from lower oil prices, some strong earnings, and solid buying from retail investors. At the same time, hedge funds continue to... Here Are Wednesday's Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technologies, Reddit, and More
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.82 per share a year ago.
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027 Well-capitalized with $1.55 billion in cash as of March 31, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.
B. Metzler seel. Sohn and Co. AG purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,607 shares of the company's stock, valued at approximately $1,214,000. Other institutional investors and hedge
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) Director Bruce Booth sold 4,159 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $89.97, for a total transaction of $374,185.23. Following the sale, the director owned 4,159 shares of the company's stock, valued at $374,185.23.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) COO Jeremy Chadwick sold 5,251 shares of the business's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total transaction of $472,590.00. Following the transaction, the chief operating officer owned 61,202 shares of the
Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.
Kymera Therapeutics remains a "Strong Buy", driven by positive phase 1b data for KT-621 in atopic dermatitis and pipeline expansion. KT-621 achieved a mean 63% EASI reduction and 40% pruritus NRS reduction, supporting advancement into phase 2b BROADEN2 [AD] and BREADTH [asthma] trials. Both AD and asthma programs received FDA Fast Track Designation, with mid-2027 [BROADEN2] and late-2027 [BREADTH] data readouts as key milestones.
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track designation previously granted for KT-621 for moderate to severe AD WATERTOWN, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma.
Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.
SG Americas Securities LLC boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 169.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,693 shares of the company's stock after buying an additional 14,261 shares during the